Syneos Health, Inc.
SYNH
NASDAQ37.58
Syneos Health, Inc.
NASDAQ:SYNH
RECENT
PRICE
37.58
P/E
RATIO
12.81
(PEG:0.58)
P/E RATIO
RELATIVE
TO S&P
0.58
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.69 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 02/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
- -
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.64
(1.15)
(0.45)
0.09
16.74
(1.14)
0.64
0.01
16.55
(0.69)
0.33
0.01
22.12
(0.44)
1.99
0.01
24.17
2.02
3.17
- -
29.81
2.08
1.44
- -
35.67
(1.85)
2.06
- -
42.45
0.23
2.41
- -
45.13
1.27
2.46
- -
42.39
1.85
3.60
- -
50.19
2.26
3.79
- -
52.40
2.79
3.80
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.09
- -
0.18
6.10
0.29
4.59
0.48
7.36
0.36
3.76
0.58
5.58
0.59
40.35
0.53
27.62
0.62
29.24
0.48
31.12
0.55
32.85
0.94
32.46
CAPEX per share
Book Value per share
- -
- -
- -
- -
- -
52
52
60
53
58
54
75
103
104
104
104
103
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(52.9)
(2.9)
0.0%
18.7
0.9
- -
21.3
1.0
- -
(27.4)
(1.2)
- -
188.4
7.5
- -
38.8
1.6
- -
31.6
0.8
- -
38.1
1.3
- -
12.8
0.6
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$4,844 m.
Total assets
$8,198 m.
Long-term debt
$2,983 m.
Cash and equiv.
$170 m.
Goodwill $4,850 m.
Retained earnings $112 m.
Common stock 103 m. shares
Market Capitalisation
$3,903 m. (as of 6/2/23)
656
(6.1)%
869
(4.3)%
995
3.2%
1,179
5.4%
1,399
10.9%
1,611
9.6%
2,672
(1.1)%
4,390
3.6%
4,676
5.1%
4,416
6.6%
5,213
7.5%
5,407
8.1%
Revenue (m)
Operating margin
64
(60)
79
(59)
58
(42)
55
(23)
56
117
59
113
180
(138)
274
24
242
131
222
193
236
235
249
287
Depreciation (m)
Net profit (m)
36.8%
(9.1)%
37.7%
(6.8)%
(35.4)%
(4.2)%
16.8%
(2.0)%
10.6%
8.4%
16.0%
7.0%
(23.8)%
(5.2)%
57.6%
0.6%
(29.1)%
2.8%
5.3%
4.4%
25.5%
4.5%
24.8%
5.3%
Income tax rate
Net profit margin
- -
- -
- -
44
588
317
58
587
276
47
415
392
(53)
472
217
56
486
301
263
2,966
3,023
(11)
2,764
2,856
46
2,806
3,030
161
3,155
3,242
112
3,016
3,413
240
2,983
3,354
Working capital (m)
Long-term debt (m)
Equity (m)
- -
- -
- -
(2.1)%
(2.6)%
(18.7)%
4.5%
2.4%
(15.0)%
2.4%
2.0%
(6.0)%
17.8%
12.1%
53.8%
14.9%
11.3%
37.4%
(1.0)%
(0.7)%
(4.6)%
1.4%
2.6%
0.9%
5.0%
3.1%
4.3%
4.3%
3.7%
5.9%
4.5%
4.8%
6.9%
5.4%
5.6%
8.6%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
164
272
106
Receivables
1,304
1,345
1,525
Inventory
- -
- -
- -
Other
95
121
135
Current assets
1,562
1,738
1,766
Acc. Payable
137
114
108
Debt due
114
60
64
Other
1,266
1,404
1,483
Current liab.
1,516
1,577
1,654
107.6%
- -
100.8%
- -
101.2%
- -
101.6%
- -
100.0%
156.0%
100.0%
82.7%
100.0%
- -
100.0%
30.1%
100.0%
22.3%
100.0%
18.7%
100.0%
29.9%
100.0%
38.2%
Plowback ratio
Div.&Repurch. to FCF
Syneos Health, Inc. (US) started trading on November 5, 2014 (cik: 0001610950), operates in the Healthcare sector (Diagnostics & Research industry), has 26,751 full-time employees, and is led by Mr. Alistair Macdonald. Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
20.82%
24.00%
Cash flow
28.95%
69.96%
Earnings
97.91%
-56.33%
Dividends
- -
- -
Book value
3.21%
104.30%
Insider trading
Type
Shares
Date
Kralowetz Donna Hildebrand
Award
7,064
01/19/23
Kralowetz Donna Hildebrand
InKind
211
01/18/23
Tucat Christian
InKind
679
01/18/23
Brooks Michael Lee
InKind
561
01/18/23
Brooks Michael Lee
InKind
1,159
01/18/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
1,163
1,013
1,099
1,140
4,416
2021
1,209
1,283
1,348
1,373
5,213
2022
1,336
1,361
1,336
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.32
0.04
0.61
0.88
1.85
2021
0.37
0.40
0.75
0.73
2.26
2022
0.45
0.76
0.85
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -